ANAB Stock Cash Flow Statements

AnaptysBio Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

AnaptysBio Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31

cash flows from operating activities:
net income	-38,630,000	-39,329,000	-21,784,000	-32,851,000	-46,660,000	-43,936,000	-42,211,000	-37,308,000	-39,845,000	-44,255,000	-26,413,000	-33,502,000	-32,554,000	-36,255,000	-32,538,000	-6,666,000	-429,000	-18,163,000	33,646,000	-23,767,000	-21,548,000	-8,262,000	-20,263,000	-31,033,000	-23,962,000	-22,078,000	-16,994,000	-15,958,000	-13,618,000	-15,086,000	-6,861,000	-9,090,000	-2,684,000	-11,435,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	142,000	146,000	145,000	144,000	154,000	163,000	165,000	158,000	163,000	166,000	184,000	166,000	163,000	162,000	165,000	169,000	160,000	125,000	144,000	138,000	137,000	140,000	140,000	135,000	124,000	115,000	106,000	91,000	64,000	54,000	47,000	46,000	51,000	39,000
stock-based compensation	9,239,000	9,170,000	8,184,000	8,189,000	7,544,000	10,131,000	8,111,000	7,807,000	8,427,000	8,860,000	6,685,000	6,271,000	6,658,000	7,742,000	3,978,000	4,364,000	3,690,000	3,315,000	2,978,000	2,805,000	2,741,000	2,975,000	2,757,000	3,144,000	3,643,000	2,867,000	2,621,000	2,532,000	2,548,000	2,260,000	1,132,000	942,000	1,438,000	866,000
accretion/amortization of investments	-1,597,000	-1,667,000	-2,302,000	-2,566,000	-2,477,000	-2,968,000	-3,154,000	-2,993,000	-2,183,000	-2,191,000	-1,723,000			161,000	100,000	100,000	126,000	167,000	222,000	178,000	69,000	-8,000	-184,000	-523,000
amortization of right-of-use assets – operating	459,000	460,000	456,000	452,000	441,000	442,000	439,000	434,000	424,000	427,000	422,000	419,000	408,000	411,000	220,000	500,000
non-cash interest expense	19,606,000	18,061,000		15,413,000	10,953,000	6,317,000	4,958,000	4,431,000	4,358,000	4,336,000	4,251,000	6,135,000	5,868,000	4,854,000									173,000	171,000	168,000	164,000	165,000	164,000	161,000	156,000	159,000	157,000
changes in operating assets and liabilities:
receivables from collaborative partners	-3,534,000	22,881,000	-28,570,000	-3,188,000	-1,918,000	-238,000	-3,582,000	-87,000	-1,659,000	-104,000	-239,000	-147,000	-112,000	-45,000	-115,000
prepaid expenses and other assets	414,000	530,000	299,000	1,405,000	3,065,000	-1,566,000	2,843,000	-5,796,000	-1,292,000	51,000	1,705,000	2,821,000	-4,118,000	-1,221,000	6,740,000	-5,306,000	-959,000	-2,276,000	5,008,000	-424,000	-2,711,000	233,000	253,000	490,000	2,649,000	-1,214,000	-3,785,000	-217,000	-1,574,000	388,000	-304,000	909,000	-2,347,000	-143,000
accounts payable and other liabilities	-22,320,000	-24,034,000	-40,047,000	3,364,000	8,018,000	-5,172,000	-1,498,000	-2,702,000	6,605,000	8,533,000	4,832,000	1,257,000	75,000	3,536,000	-5,321,000	-191,000	5,897,000	-5,125,000	-4,446,000	4,057,000	-3,298,000	-5,190,000	1,319,000	520,000	7,584,000	5,076,000	1,137,000	3,849,000	2,255,000	-158,000	1,137,000	-1,019,000	1,418,000	682,000
operating lease liabilities	-479,000	-462,000	-457,000	-452,000	-442,000	-426,000	-420,000	-418,000	-407,000	-391,000	-389,000	-383,000	-374,000	-359,000	20,000	158,000
net cash from operating activities	-40,244,000	-10,700,000	-66,672,000	-10,090,000	-21,322,000	-37,253,000	-34,349,000	-36,474,000	-25,409,000	-24,568,000	-10,685,000	-17,747,000	-24,147,000	-21,014,000	-25,301,000	-7,006,000	9,591,000	-23,204,000	37,578,000	-17,013,000	-19,610,000	-15,112,000	-15,805,000	-22,096,000	-15,517,000	-16,099,000	-12,290,000	-14,860,000	-8,878,000	-12,478,000	-4,810,000	-3,888,000	-2,643,000	-8,097,000
capex	-39,000	-35,000	-263,000	-35,000	-33,000	-27,000	-280,000	-162,000	-190,000	-175,000	-175,000	-50,000	-78,000	-55,000	-14,000	-172,000	-863,000	-317,000	-311,000	-88,000	-83,000	-87,000	-104,000	-280,000	-241,000	-180,000	-206,000	-321,000	-304,000	-232,000	-124,000	-13,000	-68,000	-85,000
free cash flows	-40,283,000	-10,735,000	-66,935,000	-10,125,000	-21,355,000	-37,280,000	-34,629,000	-36,636,000	-25,599,000	-24,743,000	-10,860,000	-17,797,000	-24,225,000	-21,069,000	-25,315,000	-7,178,000	8,728,000	-23,521,000	37,267,000	-17,101,000	-19,693,000	-15,199,000	-15,909,000	-22,376,000	-15,758,000	-16,279,000	-12,496,000	-15,181,000	-9,182,000	-12,710,000	-4,934,000	-3,901,000	-2,711,000	-8,182,000
cash flows from investing activities:
purchases of investments	-54,208,000	-122,547,000		-51,345,000	-149,152,000	-58,997,000		-70,048,000	-119,009,000	-48,555,000		-180,130,000	-172,318,000	-322,477,000		-16,748,000
sales and maturities of investments	90,650,000	137,429,000	91,749,000	110,000,000	146,743,000	127,640,000	115,765,000	100,845,000	98,744,000	134,126,000	149,250,000	147,746,000	101,400,000	9,620,000	25,500,000	27,744,000	42,320,000	63,284,000	42,264,000	74,445,000	88,411,000	84,851,000	80,905,000	102,879,000	110,667,000	89,600,000	57,598,000	58,520,000	55,450,000	34,581,000	27,271,000
purchases of property and equipment	-39,000	-35,000	-263,000	-35,000	-33,000	-27,000	-280,000	-162,000	-190,000	-175,000	-175,000	-50,000	-78,000	-55,000	-14,000	-172,000	-863,000	-317,000	-311,000	-88,000	-83,000	-87,000	-104,000	-280,000	-241,000	-180,000	-206,000	-321,000	-304,000	-232,000	-124,000	-13,000	-68,000	-85,000
net cash from investing activities	36,403,000	14,847,000	-29,396,000	58,620,000	-2,442,000	68,616,000	49,178,000	30,635,000	-20,455,000	85,396,000	21,497,000	-32,434,000	-70,996,000	-312,912,000	-66,694,000	10,839,000	37,961,000	56,729,000	3,598,000	4,732,000	75,394,000	10,751,000	4,035,000				-166,150,000	24,615,000	-3,062,000	2,146,000	-153,057,000	-495,000	-62,421,000	-27,085,000
cash flows from financing activities:
proceeds from issuance of common stock	1,423,000	290,000	555,000	4,128,000	979,000	811,000	264,000	160,000	783,000	1,265,000	3,419,000	2,699,000	865,000	4,844,000
repurchase and retirements of common stock	-51,098,000	-4,424,000						0	-12,474,000	-37,526,000
proceeds from the sale of future royalties			0	0							0
payment for net share settlement of equity awards	0	-1,451,000	0	0	0	-7,504,000
principal repayment of liability for sale of future royalties	-823,000	-23,005,000
payments for debt issuance costs				-67,000				0	0	-43,000		-288,000	0	-2,000
net cash from financing activities	-50,498,000	-28,590,000	27,567,000	71,230,000	41,890,000	-13,633,000	-5,159,000	-3,072,000	-13,492,000	-37,574,000		37,027,000	432,000	4,609,000		241,000	554,000	167,000	126,000	263,000	71,000	-1,339,000	-111,000	-1,421,000	-1,660,000	-1,301,000	-1,372,000	226,596,000	-477,000	-1,383,000	212,387,000	300,000	-938,000	80,704,000
net increase in cash and cash equivalents	-54,339,000	-24,443,000	-68,501,000	119,760,000	18,126,000	17,730,000				23,254,000		-13,154,000	-94,711,000	-329,317,000
cash and cash equivalents, beginning of period	0	123,080,000	0	0	0	35,965,000
cash and cash equivalents, end of period	-54,339,000	98,637,000	-68,501,000	119,760,000	18,126,000	53,695,000
supplemental disclosure of cash flow information
interest portion of repayment for sale of future royalties	17,804,000	18,100,000
income taxes paid	39,000	5,000
non-cash investing and financing activities:
amounts accrued for issuance costs related to the sale of future royalties											56,000	-104,000	0	128,000
amounts accrued for repurchases of common stock	-479,000	959,000						-13,000	-818,000	1,290,000
receivable related to issuance of common stock, upon exercise of stock options							0	0	-8,000	-43,000	32,000	-9,000
deferred income		3,544,000
amounts accrued for property and equipment		11,000	3,000				-271,000	227,000	14,000	38,000	126,000			19,000	20,000	-78,000	31,000	58,000	114,000	140,000	-61,000	86,000	-41,000	68,000	-219,000	233,000	-1,000	-34,000	187,000	7,000	179,000	3,000	-43,000	52,000
non-cash interest expense for sale of future royalties
purchase of investments
proceeds from public offerings, net of underwriters' fees																											0
payments for repurchase of common stock
payments for offering costs			-122,000																										0	-280,000	-102,000	-12,000	-1,086,000	-399,000
payments for issuance costs related to the sale of future royalties
amounts accrued for repurchase of common stock
proceeds from public offerings, net of underwriters’ fees
repayment of liability for sale of future royalties				-26,830,000	-9,053,000	-6,940,000	-5,423,000	-3,232,000	-1,801,000	-1,270,000	-1,424,000	-384,000	-433,000	-233,000
amounts accrued for offering costs																															-178,000			1,290,000
gain on disposal of property and equipment
proceeds from the sale of property and equipment															0
net increase in cash, cash equivalents, and restricted cash															159,341,000	4,074,000	48,106,000	33,692,000	41,302,000	-12,018,000			-11,881,000	36,346,000			-179,812,000			-11,715,000				45,522,000
cash, cash equivalents and restricted cash, beginning of period							0	0	0	71,308,000	0	0	0	495,729,000	0	0	0	250,516,000	0	0	0	171,077,000	0	0	0	113,656,000	0	0	0	81,249,000	0	0	0	51,292,000
cash, cash equivalents and restricted cash, end of period							9,670,000	-8,911,000	-59,356,000	94,562,000	12,761,000	-13,154,000	-94,711,000	166,412,000	159,341,000	4,074,000	48,106,000	284,208,000	41,302,000	-12,018,000	55,855,000	165,377,000	-11,881,000	36,346,000	40,699,000	105,913,000	-179,812,000	236,351,000	-12,417,000	69,534,000	54,520,000	-4,083,000	-66,002,000	96,814,000
leased assets obtained in exchange for operating lease liabilities															0	0
net decrease in cash and cash equivalents								-8,911,000
(gain) loss on disposal of property and equipment, net of gain on lease termination
payments on notes payable																			0	0	0	-1,375,000	-1,875,000	-1,875,000	-1,875,000	-1,875,000	-1,875,000	-1,875,000	-1,875,000	-1,250,000
net cash provided (used in) by financing activities
interest paid																			0	0	0	4,000	40,000	83,000	129,000	172,000	208,000	250,000	288,000	297,000	327,000	293,000	191,000	278,000
australian tax incentive receivable																							0	0	175,000	-1,000	-1,000	-21,000	1,458,000	-9,000	-115,000	4,151,000	-672,000	-847,000
proceeds from issuance of common stock, upon the exercise of stock options																241,000	554,000	167,000	126,000	263,000	71,000	36,000	1,764,000	454,000	215,000	574,000	731,000	669,000	1,397,000	72,000	165,000	311,000	148,000	355,000
receivable from collaborative partners																	605,000	-1,247,000				-5,000,000									0	0	0	1,225,000
acquisition of investments																		-6,238,000	-38,355,000	-69,625,000	-12,934,000	-74,013,000	-76,766,000	-42,736,000	-52,550,000	-79,763,000	-223,542,000	-33,584,000	-58,208,000	-32,203,000	-180,204,000	-21,348,000	-62,353,000	-27,000,000
income taxes
loss on disposal of property and equipment, net of gain on lease termination
proceeds from issuance of common stock, upon the exercise of warrants																											0	0	1,000	75,000	0	1,000	0	535,000
net decrease in cash, cash equivalents, and restricted cash																						-5,700,000				-7,743,000						-4,083,000
change in fair value of liability for preferred stock warrants																															0	0	0	1,366,000
reclassification of warrants to equity																															0	0	0	4,607,000
proceeds for offering costs
net provided by investing activities																									57,876,000	9,657,000
accretion of discount on investments																										-1,028,000
(income) income from investments																											-678,000			-83,000
loss on disposal of property and equipment
deferred revenue
proceeds from debt
fair value of warrants issued with debt
proceeds (payments) for offering costs
income from investments																															-5,000
income taxes payable
proceeds from the issuance of preferred stock, net of issuance cost
noncash investing and financing activities:
proceeds from initial public offering, net of underwriters fees																																0	0	80,213,000
noncash interest expense																																		150,000
restricted cash
proceeds from sale of property and equipment
proceeds from the issuance of preferred stock, net of issuance costs
payments for deferred offering costs
amounts accrued for deferred financing costs
conversion of convertible promissory notes payable to related parties into shares of series c-1 preferred stock

We provide you with 20 years of cash flow statements for AnaptysBio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AnaptysBio stock. Explore the full financial landscape of AnaptysBio stock with our expertly curated income statements.

The information provided in this report about AnaptysBio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.